The Quantum Blue® rapid test combines the ease and speed of lateral flow technology (using a highly specific monoclonal antibody), with full quantification by means of a small, telephone sized reading device. The Quantum Blue® reader analyzes the signal intensity from the test and control line to give a quantitative value within minutes and is therefore an ideal tool in a point-of-care setting. Besides calprotectin, BÜHLMANN offers the possibility for therapeutic drug monitoring (TDM) as well as for CRP measurement on the Quantum Blue® reader.
The inflammation typical in Ulcerative Colitis and Crohn’s Disease is not present in IBS. It is thought that IBS affects over 30 million people in Europe and results in over 2 million visits annually to physicians. Fecal calprotectin is the ideal tool to differentiate IBS from IBD and to avoid unnecessary invasive diagnostic procedures.
The clinical course of most patients with IBD is marked by periods of remission with intermittent relapses characterized by increased intestinal inflammation. Numerous published studies by Tibble et al. and others, have studied the levels of calprotectin in patients during the course of the disease. The results show that calprotectin is a good predictor of relapse in patients with IBD, thus giving clinicians an effective tool to adapt the patients treatment accordingly and to ease the relapse severity.
Click here for more information on the Quantum Blue® calprotectin products.
BÜHLMANN has launched the first rapid test for therapeutic drug monitoring (TDM) in the market. The Quantum Blue® Adalimumab and the Quantum Blue® Infliximab assays offer trough level quantification of serum drug levels within 15 minutes. The tests use highly specific monoclonal antibodies and show a very high correlation to common ELISA assays.
Click here for more information on the Quantum Blue® Adalimumab assay.
Click here for more information on the Quantum Blue® Infliximab assay.
In addition to the calprotectin assays, BÜHLMANN offers a C-Reactive Protein (CRP) rapid test on the Quantum Blue® platform. The test can easily be combined with routine calprotectin measurements. The assay covers a range of 1 – 25 mg/L CRP in serum and takes 22 minutes. The French STORI trial has shown that combined measurement of CRP and fecal calprotectin can increase diagnostic accuracy in detecting relapses in IBD patients.
Click here for more information on the Quantum Blue® CRP assay.
Reader Manual and Instruction for Use of QBSoft Software